(BNTX) BioNTech SE - Ratings and Ratios
Oncology Vaccines,Checkpoint Antibodies,MRNA Therapies,Cellular Immunotherapies
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 43.9% |
| Value at Risk 5%th | 60.9% |
| Relative Tail Risk | -15.60% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.22 |
| Alpha | -32.00 |
| CAGR/Max DD | -0.31 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.418 |
| Beta | 0.919 |
| Beta Downside | 0.370 |
| Drawdowns 3y | |
|---|---|
| Max DD | 57.88% |
| Mean DD | 41.99% |
| Median DD | 43.13% |
Description: BNTX BioNTech SE October 14, 2025
BioNTech SE (NASDAQ:BNTX) is a German biotechnology firm focused on developing mRNA-based immunotherapies for cancer and infectious diseases. Its pipeline includes more than 20 candidates across all clinical phases, notably BNT111 (Phase 2 melanoma), BNT113 (Phase 2 head-and-neck squamous cell carcinoma), BNT116 (Phase 1 non-small cell lung cancer), and the multi-indication BNT122/RO7198457 (Phase 2 adjuvant urothelial carcinoma, colorectal, pancreatic and advanced melanoma). The company also advances late-stage assets such as BNT311/GEN1046 (Phase 3 solid tumors) and BNT327 (spanning Phase 1-3 trials for small-cell lung cancer, TNBC, neuroendocrine neoplasms, and hepatocellular carcinoma).
Key recent metrics: as of Q2 2024, BioNTech reported €2.9 billion in revenue, driven primarily by its COVID-19 vaccine partnership with Pfizer, while cash and equivalents stood at €4.1 billion, providing a runway of over three years at current burn rates. The mRNA platform’s scalability and the broader biotech sector’s 12-month forward-looking P/E median of ~30× underscore both high growth potential and valuation pressure. A material driver of future earnings is the ability to leverage the existing mRNA manufacturing network for oncology candidates, which could reduce cost-of-goods-sold (COGS) by up to 20 % relative to early-stage trials.
For a deeper quantitative assessment, the ValueRay platform offers a granular view of BNTX’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-571.6m TTM) > 0 and > 6% of Revenue (6% = 189.2m TTM) |
| FCFTA -0.03 (>2.0%) and ΔFCFTA -9.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 431.7% (prev 525.1%; Δ -93.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.02 (>3.0%) and CFO -336.1m > Net Income -571.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 7.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (239.2m) change vs 12m ago -2.21% (target <= -2.0% for YES) |
| Gross Margin 82.49% (prev 84.31%; Δ -1.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 14.41% (prev 13.57%; Δ 0.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -28.11 (EBITDA TTM -103.3m / Interest Expense TTM 17.3m) >= 6 (WARN >= 3) |
Altman Z'' 13.60
| (A) 0.64 = (Total Current Assets 15.83b - Total Current Liabilities 2.22b) / Total Assets 21.34b |
| (B) 0.86 = Retained Earnings (Balance) 18.27b / Total Assets 21.34b |
| warn (B) unusual magnitude: 0.86 — check mapping/units |
| (C) -0.02 = EBIT TTM -486.7m / Avg Total Assets 21.87b |
| (D) 6.45 = Book Value of Equity 18.49b / Total Liabilities 2.86b |
| Total Rating: 13.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 13.07
| 1. Piotroski 1.0pt |
| 2. FCF Yield -9.57% |
| 3. FCF Margin -17.85% |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda 95.33 |
| 6. ROIC - WACC (= -19.89)% |
| 7. RoE -3.04% |
| 8. Rev. Trend -59.93% |
| 9. EPS Trend -78.98% |
What is the price of BNTX shares?
Over the past week, the price has changed by -6.93%, over one month by -8.42%, over three months by -7.25% and over the past year by -16.30%.
Is BNTX a buy, sell or hold?
- Strong Buy: 13
- Buy: 3
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BNTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 137.1 | 42.8% |
| Analysts Target Price | 137.1 | 42.8% |
| ValueRay Target Price | 86 | -10.4% |
BNTX Fundamental Data Overview December 03, 2025
P/E Forward = 7.0373
P/S = 7.4284
P/B = 1.1571
P/EG = 0.0449
Beta = 1.308
Revenue TTM = 3.15b EUR
EBIT TTM = -486.7m EUR
EBITDA TTM = -103.3m EUR
Long Term Debt = 192.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 53.4m EUR (from shortTermDebt, last quarter)
Debt = 245.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -9.85b EUR (from netDebt column, last quarter)
Enterprise Value = 5.88b EUR (20.17b + Debt 245.4m - CCE 14.53b)
Interest Coverage Ratio = -28.11 (Ebit TTM -486.7m / Interest Expense TTM 17.3m)
FCF Yield = -9.57% (FCF TTM -562.7m / Enterprise Value 5.88b)
FCF Margin = -17.85% (FCF TTM -562.7m / Revenue TTM 3.15b)
Net Margin = -18.13% (Net Income TTM -571.6m / Revenue TTM 3.15b)
Gross Margin = 82.49% ((Revenue TTM 3.15b - Cost of Revenue TTM 552.0m) / Revenue TTM)
Gross Margin QoQ = 90.24% (prev 70.71%)
Tobins Q-Ratio = 0.28 (Enterprise Value 5.88b / Total Assets 21.34b)
Interest Expense / Debt = 0.16% (Interest Expense 399.1k / Debt 245.4m)
Taxrate = 216.2% (out of range, set to none) (53.4m / 24.7m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 7.12 (Total Current Assets 15.83b / Total Current Liabilities 2.22b)
Debt / Equity = 0.01 (Debt 245.4m / totalStockholderEquity, last quarter 18.48b)
Debt / EBITDA = 95.33 (negative EBITDA) (Net Debt -9.85b / EBITDA -103.3m)
Debt / FCF = 17.50 (negative FCF - burning cash) (Net Debt -9.85b / FCF TTM -562.7m)
Total Stockholder Equity = 18.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.68% (Net Income -571.6m / Total Assets 21.34b)
RoE = -3.04% (Net Income TTM -571.6m / Total Stockholder Equity 18.83b)
RoCE = -2.56% (EBIT -486.7m / Capital Employed (Equity 18.83b + L.T.Debt 192.0m))
RoIC = -10.60% (negative operating profit) (EBIT -486.7m / (Assets 21.34b - Curr.Liab 2.22b - Cash 14.53b))
WACC = 9.29% (E(20.17b)/V(20.41b) * Re(9.40%) + (debt cost/tax rate unavailable))
Discount Rate = 9.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.38%
Fair Price DCF = unknown (Cash Flow -562.7m)
EPS Correlation: -78.98 | EPS CAGR: -33.39% | SUE: 0.77 | # QB: 0
Revenue Correlation: -59.93 | Revenue CAGR: -29.16% | SUE: 1.27 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-2.03 | Chg30d=-0.067 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-2.90 | Chg30d=+0.862 | Revisions Net=+7 | Growth EPS=+24.1% | Growth Revenue=-3.2%
Additional Sources for BNTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle